Bolt Biotherapeutics Inc (BOLT)
0.6203
+0.04
(+6.31%)
USD |
NASDAQ |
Sep 27, 16:00
0.6588
+0.04
(+6.21%)
After-Hours: 20:00
Bolt Biotherapeutics Research and Development Expense (TTM): 63.24M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 63.24M |
| March 31, 2024 | 63.45M |
| December 31, 2023 | 61.54M |
| September 30, 2023 | 62.06M |
| June 30, 2023 | 66.09M |
| March 31, 2023 | 69.36M |
| December 31, 2022 | 73.12M |
| September 30, 2022 | 78.76M |
| Date | Value |
|---|---|
| June 30, 2022 | 79.13M |
| March 31, 2022 | 79.91M |
| December 31, 2021 | 75.66M |
| September 30, 2021 | 68.04M |
| June 30, 2021 | 58.24M |
| March 31, 2021 | 47.70M |
| December 31, 2020 | 40.36M |
| September 30, 2020 | 32.93M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
32.93M
Minimum
Sep 2020
79.91M
Maximum
Mar 2022
63.72M
Average
64.77M
Median
Research and Development Expense (TTM) Benchmarks
| SeaStar Medical Holding Corp | 6.213M |
| CVS Health Corp | -- |
| NovaBay Pharmaceuticals Inc | 0.043M |
| Palatin Technologies Inc | 25.13M |
| iBio Inc | 5.185M |